Personalized medicine has reached the mainstream, accounting for more new drug
approvals and a promising pipeline of candidate therapeutics. Recent advances in …

On 1–2 December 2010 worldwide leaders in the field of co-diagnostics gathered in Boston,
MA, USA, to discuss the state of predictive medicine and the complexities of biomarker …

To fully implement precision medicine, a deeper understanding of biomarkers, companion
diagnostics, and their use in clinical trials is needed. Here, we describe key events in …

Medical history has not wandered far from its original aspirations of being personalized.
Diagnostic capability has evolved from the metaphysical to the anatomical to the cellular and …

Low productivity in the pharmaceutical industry positions personalized medicine and
companion diagnostics as an attractive approach. The oncology community is enthusiastic …

Foreword Waldman & Terzic advances in our understanding of the molecular mechanisms
contributing to pathogenesis have yielded an abundance of drug targets to individualize …

Evaluating the prospects for 'personalized healthcare 'has become topical at the 10-year
anniversary of the first results from the Human Genome Project. The coincidence of this …

The number of personalized medicines and companion diagnostics in use in the United
States has gradually increased over the past decade, from a handful of medicines and tests …

Regulatory authorities expect the pharmaceutical and biotechnology industries to accelerate
their development of companion diagnostics and companion therapeutics towards the goal …

An increased understanding of the biology of cancer is leading to a dramatic shift in
oncology drug development from a largely nonspecific all-comers approach to a mechanistic …